Should HCV-related cirrhosis be a contraindication for retransplantation?

Liver Transplantation

Volumn 9, Issue 3, 2003, Pages 236-238

  Biggins, Scott W ^a   Terrault, Norah A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIVIRUS AGENT; CILUPREVIR; CORTICOSTEROID; IMMUNOGLOBULIN; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; RIBAVIRIN; SERINE PROTEINASE INHIBITOR; TACROLIMUS; UNCLASSIFIED DRUG; VIRUS ANTIBODY;

CLINICAL TRIAL; DRUG SYNTHESIS; EDITORIAL; GRAFT REJECTION; GRAFT SURVIVAL; HEPATITIS B; HEPATITIS C; HUMAN; LIVER BIOPSY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; PRIORITY JOURNAL; PROGNOSIS; RECURRENT INFECTION; REOPERATION; RESOURCE ALLOCATION; SIDE EFFECT; TREATMENT CONTRAINDICATION; TREATMENT INDICATION; TREATMENT OUTCOME;

EID: 0037341948     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2003.50048     Document Type: Editorial

References (24)

1. Markmann JF, Gornbein J, Morkowitz JS, Levy MF, Klintmalm GB, Yersiz H, et al. A simple model to estimate survival after retransplantation of liver. Transplantation 1999;647:422-430.
2. Evans RW, Manninen DL, Dong FB. An economic analysis of liver transplantation costs, insurance coverage, and reimbursement. Adv Liver Transpl 1993;22:451-473.
3. Evans RW, Manninen DL, Dong FB, McLynne DA. Is retransplantation cost effective? Transplant Proc 1993;25:1694-1697.
4. O'Grady JG. Clinical economics review: Liver transplantation. Aliment Pharmacol Ther 1997;11:445-51.
5. Rosen HR, Madden JP, Martin P. A model to predict survival following hepatic retransplantation. Hepatology 1999;29:365-389.
6. Wall WJ. Recurrent disease after liver transplantation, implications for the future. Liver Transplant Surg 1997;6:362-367.
7. Berenguer M, Prieto M, San Juan F, Rayon JM, Martinez F, Carrasco D, et al. Contribution of donor age to the recent decrease in patient survival among HCV-infected liver transplant recipients. Hepatology 2002;36:202-210.
8. Wali M, Harrison RF, Gow PJ, Mutimer D. Advancing donor liver age and rapid fibrosis progression following transplantation for hepatitis C. Gut 2002;51:248-252.
9. Prieto M, Berenguer M, Rayon J, Cordoba J, Arguello L, Carrasco D, et al. High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: Relationship with rejection episodes. Hepatology 1999;29:250-256.
10. Sheiner P, Schwartz M, Mor E, Schluger L, Theise N, Kishikawa K, et al. Severe and multiple rejection episodes are associated with early recurrence of hepatitis C after orthotopic liver transplantation. Hepatology 1995;21:30-34.
11. Rosen H, Shackleton C, Higa L, Gralnek I, Farmer D, McDiarmid S, et al. Use of OKT3 is associated with early and severe recurrence of hepatitis C after liver transplantation. Am J Gastroenterol 1997;92:1453-1457.
12. Berenguer M, Prieto M, Palau A, Rayón JM, Carrasco D, San Juan F, et al. Severe recurrent hepatitis C after liver retransplantation for hepatitis C virus-related graft cirrhosis. Liver Transpl 2003;9:228-235.
13. Ghobrial R, Farmer D, Baquerizo A, Colquhoun S, Rosen H, Yersiz H, et al. Orthotopic liver transplantation for hepatitis C: Outcome, effect of immunosuppression, and causes of retransplantation during an 8-year single-center experience. Ann Surg 1999;229:824-831.
14. Yao FY, Bass NB, Hirose R, Terrault NA, Ascher NL, Roberts JP. Prediction of survival after liver re-transplantation based on pre-operative Child-Turcotte Pugh (CPT) score and the model foe end stage liver disease (MELD) score. Hepatology 2002; 36:228A.
15. Sheiner P, Schulger L, Emre S, Thung S, Lau J, Schwartz M, et al. Retransplantation for recurrent hepatitis C. Liver Transplant Surg 1997;3:130-136.
16. Testa G, Crippin JS, Netto GJ, Goldstein RM, Jennings LW, Brkic BS, et al. Liver transplantation for hepatitis C: Recurrence and disease progression in 300 patients. Liver Transpl 2000;6: 553-561.
17. Facciuto M, Heidt D, Guarrera J, Bodian CA, Miller CM, Emre S, et al. Retransplantation for late liver graft failure: Predictors of mortality. Liver Transpl 2000;6:174-179.
18. Rosen HR, Martin P. Hepatitis C infection in patients undergoing liver retransplantation. Transplantation 1998;66:1612-1616.
19. Crippin JS, McCashland T, Terrault N, Sheiner P, Charlton MR. A pilot study of the tolerability and efficacy of antiviral therapy in hepatitis C virus-infected patients awaiting liver transplantation. Liver Transpl 2002;8:350-355.
20. Mazzaferro V, Tagger A, Schiavo M, Regalia E, Pulvirenti A, Ribero ML, et al. Prevention of recurrent hepatitis C after liver transplantation with early interferon and ribavirin treatment. Transplant Proc 2001;33:1355-1357.
21. Sheiner P, Boros P, Klion F, Thung S, Schluger L, Lau J, et al. The efficacy of prophylactic interferon alfa-2b in preventing recurrent hepatitis C after liver transplantation. Hepatology 1998;28:831-838.
22. Terrault NA, Khalil M, Bollinger K, Roberts JP, Ascher NL. Limitations in the use of prophylactic antiviral strategy in hepatitis C infected patients undergoing liver transplantation. Hepatology 2002;36:177A.
23. Krawczynski K, Alter M, Tankersley D, Beach M, Robertson B, Lambert S, et al. Effect of immune globulin on the prevention of experimental hepatitis C virus infection. J Infect Dis 1996;173: 822-828.
24. Hinrichsen H, Benhamou Y, Reiser M, Sentjens R, Wedemeyer H, Hochshule M, et al. First report on the antiviral efficacy of BILN 2061, a novel oral HCV serine protease inhibitor, in patients with chronic hepatitis C genotype 1. Hepatology 2002; 36:379A.